Supplementary Table S13 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients

作者：Vivek Subbiah, Peter Paul Yu, Rangaprasad Sarangarajan, Michael A. Kiebish, Leonardo O. Rodrigues, Gregory M. Miller, Viatcheslav R. Akmaev, Shen Luan, John P. McCook, Nikunj Tanna, Tracey Reilly, Emily Chen, Valerie Bussberg, Shobha Ravipaty, Vivek K. Vishnudas, Stéphane Gesta, David Lucius, Can Bruce, Suwagmani Hazarika, Arianne Lyng, Allison Klotz, Vladimir Tolstikov, Janice R. Stevens, Victoria S. Chua, Elder Granger, Poornima K. Tekumalla, Ely Benaim, Vijay Modur, Marc S. Rudoltz, Paul Y. Song, Scott T. Tagawa, Andrew Hendifer, Sant P. Chawla, Manish A. Shah, David S. Hong, Ralph Zinner, Niven R. Narain, Madappa N. Kundranda · 年份：2025 · DOI：10.1158/2767-9764.30944133 · 研究领域：Cancer, Hypoxia, and Metabolism、Advanced Proteomics Techniques and Applications、Mitochondrial Function and Pathology

<p>. Proteomic analysis of plasma, urine, and buffy coat revealed a distinct association between BPM31510IV treatment and the regulation of complement and coagulation events. Total hits are the number of significant regression models for each protein (false-discovery rate <0.1). Additional columns refer to the proportion of significant regression models in which the protein is increasing or decreasing; proteins with ten or more hits are listed.</p>